摘要
与常规CT和MRI影像学检查相比,^(68)Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)-生长抑素类似物(SSA)PET/CT在神经内分泌肿瘤(NEN)的诊断中具有较高的灵敏度和特异度,同时,在疗效评价和预后评估等方面也有重要的指导价值。^(18)F-氟脱氧葡萄糖(FDG)PET/CT虽然在NEN的诊断中未被常规推荐,但其在良恶性肿瘤的鉴别诊断和预后评估中可提供额外的信息。笔者就近年来^(18)F-FDG和^(68)Ga-DOTA-SSA双示踪剂PET/CT在NEN中的临床应用进行综述。
Compared with conventional CT and MRI imaging examinations,^(68)Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid(DOTA)-somatostatin analog(SSA)PET/CT has higher sensitivity and specificity in the diagnosis of neuroendocrine neoplasm(NEN),and it also has important guiding value in the evaluation of curative effect and prognosis.Although not routinely recommended in the diagnosis of NEN,^(18)F-fluorodeoxyglucose(FDG)PET/CT can provide complementary information in the differential diagnosis of benign and malignant tumors and the evaluation of prognosis.An overview of the clinical application of^(18)F-FDG and ^(68)Ga-DOTA-SSA dualtracer PET/CT in NEN is presented.
作者
赵润泽
张一帆
Zhao Runze;Zhang Yifan(Department of Nuclear Medicine,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
出处
《国际放射医学核医学杂志》
2021年第9期585-590,共6页
International Journal of Radiation Medicine and Nuclear Medicine
基金
国家自然科学基金(81971644、81671720)。
